Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT00544804 2014-07-02

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Phase 1 Completed

41 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00470847 2014-05-22

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Phase 1 Completed

35 enrolled 10 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00513058 2014-01-14

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Phase 1 Completed

33 enrolled

Breast

Breast Neoplasms

NCT00316875 2013-11-08

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Phase 1 Completed

23 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01184482 2013-10-31

TYKERB-ITUX 1

Phase 1 Completed

22 enrolled

GastrointestinalHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT00495872 2012-10-18

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Phase 1 Completed

204 enrolled

Other solid neoplasm

Solid Tumors

NCT00614978 2012-09-19

LAPTEM

Phase 1 Completed

18 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00389922 2012-04-19

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

22 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00804310 2012-03-28

UCDCC#207

Phase 1 Terminated

5 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01454479 2011-10-19

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Phase 1 Unknown

24 enrolled

Gynecologic

Endometrial Neoplasms

NCT00317434 2009-12-15

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Phase 1 Terminated

12 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Bevacizumab in Multiple Phase I Combinations

STELA

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Lapatinib and Bortezomib in Patients With Advanced Malignancies

CAELYX

Lapatinib With Sirolimus or Metformin

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

CELAVIE

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

TYKERB-ITUX 1

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

LAPTEM

Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors

UCDCC#207

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer